CLINICAL TRIAL SUMMARY

MDACC Study No:2003-0767 (clinicaltrials.gov NCT No: NCT00479089)
Title:PHASE II TRIAL OF WEEKLY DOCETAXEL (TAXOTERE) VS. WEEKLY DOCETAXEL IN COMBINATION WITH ZD1839 (Iressa® ) AS CONSOLIDATION THERAPY FOR METASTATIC UROTHELIAL CANCER FOLLOWING MAXIMAL RESPONSE TO MULTI-AGENT CHEMOTHERAPY.
Principal Investigator:Arlene Siefker-Radtke
Treatment Agent:Docetaxel; ZD1839
Study Status:Closed
Study Description:The goal of this clinical research study is to compare Taxotere (docetaxel)
alone to docetaxel given with Iressaâ (ZD1839, Geftinib) in delaying the return
of bladder cancer in patients who have already responded to chemotherapy. The
safety of these two treatments will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Bladder
Phase of Study:Phase II
Treatment Agents:Docetaxel
ZD1839
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Variable
Supported By:N/A
Return Visit:Every cycle (approximately 5-6 weeks)
Home Care:Patients may receive care at home under the guidance of their local oncologist.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Arlene Siefker-Radtke
Dept:Genitourinary Medical Oncology
For Clinical Trial Enrollment:713-792-2830
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults